For the past two decades, single-use disposable autoinjectors have become the predominant drug delivery device to treat immunosuppressive and inflammatory diseases, and a range of other health conditions. Autoinjectors have evolved to become more compact, reliable, and easy to use; however, these devices also possess certain suboptimal characteristics associated with single-use products. New innovations can now overcome the challenges of traditional disposable autoinjector technology, while providing a proven platform for pharmaceutical companies.
Bill Welch, Chief Technology Officer, Phillips-Medisize, a Molex company
As Chief Technology Officer, Bill Welch leads the Phillips-Medisize global pre-production organization, a 700-person team spanning front-end innovation, development, and new product introduction. Welch’s program-focused organization regularly has more than 50 programs running concurrently along the development and launch continuum, and he leads the company’s global expansion for manufacturing and development.
With nearly 30 years of contract development and manufacturing experience, Welch has a bachelor’s degree from the University of Minnesota at Duluth, serves on the industry advisory board for the Plastics Engineering program at the University of Wisconsin-Stout, and is a board member of an inhaled drug delivery platform company.Message Presenter
Who Should Attend?
This webinar will appeal to managers and above at small-to-large pharma/medical device companies and job functions including, but not limited to:
- Pharma engaging in landscaping the injection market
- Pharma device engineers engaged in device selection (R&D/Supply)
- Pharma sustainability lead (environmental)
What You Will Learn
Join this webinar and learn:
- Why disposable, single use autoinjectors, introduced in the early 2000s, can no longer satisfy today’s requirements to reduce space, storage, and waste
- The growing demand for drug delivery device connectivity to improve patient adherence, care team collaboration, and health outcomes
- How pharmaceutical companies can create a clear path to low cost connectivity with more affordable, convenient, and sustainable injection devices
- Examples of smart, reusable, autoinjectors that work with mobile apps to track and transmit digital data from patients to physicians
- Key considerations when embracing a connected health platform for biologic and injectable drugs
Phillips-Medisize, LLC, a Molex company, is an end-to-end provider of innovation, development and manufacturing solutions to the pharmaceutical, diagnostics and medical device market segments. Backed by the combined global resources of Molex and its parent company Koch Industries, Phillips-Medisize’s core advantage is the knowledge of its people to integrate design, molding, electronics and automation, providing innovative, high-quality manufacturing solutions.